"Patients who have chosen to undergo DecisionDx-UM already know the importance of genetic testing in the management and follow-up care of their disease," said Derek Maetzold, CEO of Castle Biosciences. "We believe it is important to offer this new tissue repository service which will expand patient and physician access to future testing."
For more information, please visit www.MyUvealMelanoma.com
About Uveal Melanoma
Although it is rare, and its cause not well understood, uveal melanoma is the most common form of eye cancer in the United States, with about 2,000 diagnoses per year. This form of eye cancer, sometimes referred to as ocular melanoma, may occur in any of the three parts of the uvea. For this reason, it is sometimes referred to as choroidal, ciliary body, or iris melanoma based upon its exact location. The choroid is the most common place for a tumor to develop.
Similar to other melanomas, uveal melanoma begins in cells called melanocytes that help produce the pigments of the skin, hair, and eyes. While most patients are middle-aged with fair skin, uveal melanoma can and has affected people of all complexions and ages. Treatments for the primary uveal melanoma tumors are highly effective; however, there is currently no cure for metastatic disease.
The DecisionDx-UM test measures the gene expression profile (GEP), or molecular signature, of an individual's tumor and identifies with high accuracy the likelihood of metastasis. The test requires a sample of the patient's tumor that is obtained prior to radiation surgery, the most common therapy used in the treatment of uveal melanoma.
The DecisionDx-UM test is standard of care in the management of uveal melanoma in
|SOURCE Castle Biosciences Inc.|
Copyright©2012 PR Newswire.
All rights reserved